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in DMD, resulting in loss of dystrophin, which is essential to
muscle health. DMD “exon skipping” uses anti-sense oligo-
nucleotides (AONs) to force specific exon exclusion during
mRNA processing to restore reading frame and rescue of
partially functional dystrophin protein. Although exon-
skipping drugs in humans show promise, levels of rescued dys-
trophin protein remain suboptimal. We previously identified
dantrolene as a skip booster when combined with AON in
human DMD cultures and short-term mdx dystrophic mouse
studies. Here, we assess the effect of dantrolene/AON combina-
tion on DMD exon-23 skipping over long-term mdx treatment
under conditions that better approximate potential human
dosing. To evaluate the dantrolene/AON combination treat-
ment effect on dystrophin induction, we assayed three AON
doses, with and without oral dantrolene, to assess multiple
outcomes across different muscles. Meta-analyses of the results
of statistical tests from both the quadriceps and diaphragm
assessing contributions of dantrolene beyond AON, across all
AON treatment groups, provide strong evidence that dantro-
lene modestly boosts exon skipping and dystrophin rescue
while reducing muscle pathology in mdx mice (p < 0.0087).
These findings support a trial of combination dantrolene/
AON to increase exon-skipping efficacy and highlight the value
of combinatorial approaches and Food and Drug Administra-
tion (FDA) drug re-purposing for discovery of unsuspected
therapeutic application and rapid translation.Received 5 November 2017; accepted 6 February 2018;
https://doi.org/10.1016/j.omtn.2018.02.002.
7These authors contributed equally to this work.
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Duchenne muscular dystrophy (DMD) is the most common lethal
genetic disease of childhood, with an incidence that ranges from
10.7 to 27.8 per 100,000 population.1 DMD is mainly caused by
frameshifting multi-exon deletions in the DMD gene, resulting in
loss of expression of the encoded protein, dystrophin, which is critical
to muscle cell health.2 Dystrophin stabilizes the muscle membrane in
the context of contraction by linking the cytoskeleton to the extracel-180 Molecular Therapy: Nucleic Acids Vol. 11 June 2018 ª 2018 The A
This is an open access article under the CC BY license (http://creatilular matrix through N-terminal association with F-actin and
C-terminal association with the dystrophin-associated glycoprotein
complex (DGC). The DGC spans the membrane and binds laminin
a2 within the basal lamina and requires dystrophin for its sarco-
lemmal localization, stability, and function. Additionally, dystrophin
and the DGC contribute to muscle cell signaling and stem cell self-
renewal.3
Loss of dystrophin and DGC expression results in muscle membrane
damage, altered signaling, and defective muscle regeneration.
Membrane damage drives increased intracellular Ca2+ levels, calpain
activation, protein degradation, and cell death.4 Proper nitric oxide
synthase (NOS) localization at the DGC is lost in the absence of dys-
trophin, resulting in hyper-nitrosylation of the ryanodine receptor 1
(RyR1),5 which also contributes to Ca2+ dysregulation. Inflammation
and replacement of muscle with fat and fibrosis further interferes with
muscle regeneration and function. Over time, this leads to progressive
loss of body-wide skeletal muscle and cardiac function. Boys with
DMD typically become dependent on a wheelchair between ages 10
and 13 years and often succumb to respiratory and/or cardiac failure
between the ages of 18 and 30 years.
Becker muscular dystrophy (BMD), a milder form of dystrophy, is
also caused by mutations in DMD.6,7 However, in most instances,
DMD mutations in those with BMD preserve the mRNA reading
frame and lead to the production of an internally deleted dystrophin
protein with partial functionality. BMD patients can range in severity
from loss of ambulation at 16 years old to asymptomatic, dependinguthors.
vecommons.org/licenses/by/4.0/).
www.moleculartherapy.orglargely on the stability and functionality of the mutant dystrophin. Of
note, several in-frame Becker-causing DMDmutations cluster within
a hotspot between exons 45 and 55 and encode internally deleted
dystrophin proteins with partial functionality responsible for a milder
disease course relative to Duchenne.8 These findings provide the
rationale for therapies aimed at reframing mRNA to rescue Becker-
like dystrophin proteins with partial functionality.
One therapeutic strategy, termed exon skipping, forces targeted exon
exclusion during pre-mRNA splicing to restore the DMD reading
frame through systemic administration of anti-sense oligo-nucleo-
tides (AONs).9–11 Reframing by exon skipping rescues the expression
of a BMD-like internally deleted dystrophin. AON-guidedDMD exon
skipping has proven effective in rescuing a Becker-like dystrophin
protein and improving skeletal muscle function in both mouse and
dog DMD models.12–14
Exondys51, a morpholino AON designed to restore theDMD reading
frame by excluding exon 51, was recently granted accelerated
approval in the USA and is relevant to 13% of DMD patients.15–21
In a small multi-year study, 12 boys who were amenable to reframing
by skipping exon 51 were administered Exondys51 weekly by intrave-
nous infusion.17 All patients received 30 mg/kg, except for one who
received 50 mg/kg. After 3 years, those treated with Exondys51
were reported to walk 151 m further than predicted by a longitudinal
natural history of DMD boys from a cohort well-matched for geno-
type, age, and functional parameters at study initiation. By year 4,
only 20% of Exondys51-treated subjects were reported to have lost
ambulation, whereas 80% of the matched historical control lost
ambulation over the same time frame.17–19
Skeletal muscle biopsies from subjects administered Exondys51
demonstrated a statistically significant induction of dystrophin
relative to pre-treatment control biopsies and, ultimately,
accelerated approval was granted based on this biomarker.16,18–21
Levels of induced dystrophin ranged from 0% to 2.47% of normal
(as determined by western blot), distributed across an average of
16% of myofibers (as determined by immunofluorescence of dys-
trophin-positive fibers). Although no lower threshold requirement
for dystrophin expression has been firmly established, very low
levels have been reported to be associated with some functional
benefit in mouse models and human DMD/BMD.22–24 Some
BMD patients have been reported to express as low as 3% of
wild-type levels of internally deleted dystrophin.22,23 Although
these patients present with “severe BMD,” they are less severe
than typical DMD. Western blot analysis has not been performed
to allow robust quantitation against a human dystrophin protein
standard, limiting clear delineation of the lower limit of dystrophin
needed for any degree of functional benefit. Nonetheless, induction
of higher levels of dystrophin is predicted to impart greater
function.
We previously identified dantrolene as a booster of antisense-
mediated exon skipping through an unbiased small molecule screenand validated its efficacy in short-term mdx mouse and human
DMD myotube culture models.25 The mdx mouse has a premature
termination within exon 23 of DMD, leading to loss of dystrophin
and muscular dystrophy. Intravenous administration of e23AON
promotes exon 23 skipping and rescue of an internally deleted
dystrophin protein that is capable of significant functionality and
rescue of the DMD-like phenotype.26,27 We have reported that
dantrolene (10 mg/kg), administered twice daily intraperitoneally
(i.p.), boosted low-dose (10 mg/kg) AON-directed exon 23 skipping
(e23AON), dystrophin protein expression, and strength in the mdx
mice over the course of short-term experiments (1–3 weeks).
Further, DMD patient-derived reprogrammed myotubes bearing an
exon 45–50 deletion treated with the dantrolene/e51AON combina-
tion induced greater levels of in-frame skipped DMD exon51
mRNA than either drug alone, establishing potential relevance to
human DMD treatment.25
Here, we assess if dantrolene has an exon skip boosting activity in the
mdx DMD mouse model in the context of long-term 6-month
chronic treatment with weekly intravenous (i.v.) e23AON at a high
(300 mg/kg), medium (50 mg/kg), or low (10 mg/kg) dose in combi-
nation with dantrolene dosed orally. These conditions are more rele-
vant to potential combination therapy in DMD patients currently
prescribed ExonDys51 or who may be exposed to other AON drugs
currently in development. We demonstrate that dantrolene boosts
e23AON-directed DMD mRNA exon skipping, dystrophin protein
expression, and rescue of dystrophic pathology in mdx mice in the
context of long-term chronic treatment, without observed toxicity.
These findings provide data in support of the feasibility and
efficacy of repurposing dantrolene as a skip-boosting drug for use
in combination with exon-skipping AON. Because dantrolene and
Exondys51 are both Food and Drug Administration (FDA)-approved
drugs with good safety profiles in DMD, combination therapy could
be tested in humans.
RESULTS
Orally Administered Dantrolene Enhances Antisense-Mediated
Exon Skipping and Dystrophin Protein Rescue in mdx Mice
Previous studies using twice daily i.p. injections identified dantro-
lene as a booster of DMD exon skipping in short-term treatment
using non-clinical grade dantrolene (Sigma). Dantrolene is already
clinically available in tablet form for oral administration under the
trade name dantrium. Because oral dosing is much more practical
both for long-term mouse studies and translation to human DMD,
we performed a series of 3-week pilot studies to determine if
orally administered dantrium incorporated into chow ad libitum
boosted dystrophin induction of systemically administered
e23AON. We found that orally administered dantrolene adminis-
tered in combination with 50 mg/kg e23AON boosted dystrophin
immunofluorescence intensity per cross-sectional area relative
to e23AON treatment alone (Figure S1). Therefore, we relied
on oral dantrium incorporated into chow to assess dosing,
efficacy, and safety during the course of chronic combination
treatment.Molecular Therapy: Nucleic Acids Vol. 11 June 2018 181
Figure 1. Overview of Long-Term Dosing Experiment
(A) Treatment groups for 6- to 8-week-old mdx mice subjected to 6 months of combination therapy. (B) Protocol outline for long-term dosing experiment.
Molecular Therapy: Nucleic Acids6-Month Combination Therapy Promotes Increased Exon
Skipping and Dystrophin Expression in Skeletal Muscle
We next assessed the efficacy of long-term administration of combi-
nation therapy of e23AON and dantrolene inmdxmice. We designed
a blinded, placebo-controlled, multi-dose, 6-month study, in which
mdx mice were fed a diet containing 30–70 mg/kg/day dantrolene
ad libitum in combination with weekly retro-orbital injections of
e23AON at either 0, 10, 50, or 300 mg/kg (Figure 1). Experiments
were blinded and performed within recently published guidelines.28
At the beginning of the study, 6- to 8-week-old mice underwent strat-
ified randomization based on age and weight. Mice were acclimated to
the facility for 1 week. Then, using a staggered start, cohorts of 9 mice
(from random treatment groups) were initiated into the experiment
because our workflow is limited to harvest of muscles of 9 mice per
day. Mice were weighed weekly and dantrolene chow dose was
adjusted to maintain consistent dosing throughout the study. Serum
levels of dantrolene were assessed at the end of the treatment
period and demonstrated levels of 0.27 ± 0.18 mg/mL were achieved
(Figures S2A–S2C).
During the 6-month treatment, mice did not show any change in
body weight or feeding habits with dantrolene treatment. Because
of the potential for liver and kidney damage upon chronic treatment,
we assessed serum levels of g-glutamyl transferase (GGT), creatinine,
bilirubin, and blood urea nitrogen (BUN) 1 week prior to sacrificing
animals. We found no significant changes in these measures that were
reflective of kidney or liver toxicity (Figure 2) with dantrolene treat-
ment. Although dantrolene treatment did lead to an 18% decrease in
serum BUN levels in all treated groups (Figure 2), this decrease is not
likely to be biologically significant. H&E staining did not reveal any
differences in pathology of the heart, liver, and kidney associated
with e23AON and dantrolene dosing (not shown).
After 6 months of administration, levels of DMD mRNA exon
skipping were determined in the quadriceps and diaphragm using
droplet digital PCR (ddPCR) (Figure 3A). The presence or absence
of dantrolene skip boosting activity was assessed across multiple182 Molecular Therapy: Nucleic Acids Vol. 11 June 2018e23AON concentrations and quadriceps and diaphragm muscles.
Each outcome was tested separately using the same analytic approach
to assess whether dantrolene contributes to that outcome beyond
e23AON. Because these outcomes are not normally distributed, a
nonparametric two-way ANOVA (Friedman’s test) was used.29,30
The p values for each outcome were then combined over the twomus-
cle types using a meta-analysis. To illustrate, for the Friedman test of
quantitative ddPCR readouts for DMD exon 23 skipping, every
mouse was ranked across all AON and dantrolene levels, and a model
that includes e23AON levels and the presence or absence of dantro-
lene as well as the possibility of their interaction was tested for both
the quadriceps and diaphragm. Results indicate that e23AON has a
highly significant positive treatment effect when considered across
all e23AON concentrations combined relative to placebo-treated con-
trols in both the quadriceps and diaphragm analyzed independently
(p < 0.0001 for each, Figure S3). Further, dantrolene/e23AON combi-
nation treatment significantly boosts mRNA exon skipping relative to
e23AON treatment alone when all e23AON concentrations tested are
considered together (p = 0.012 for quadriceps, p = 0.0008 for dia-
phragm; Figures 3B and S3). Meta-analysis of the p values from the
quadriceps and diaphragm combined demonstrate a higher level of
significance of dantrolene/e23AON treatment on exon skipping
(p = 0.00012) (Figure 3B).
Dystrophin protein expression in mice treated with combination
therapy, both by quantitating the intensity of dystrophin immunoflu-
orescence staining (Figure 4A) and the percentage of dystrophin-pos-
itive fibers (Figure 4B) within transverse muscle sections, was also
significantly boosted when dantrolene was used in combination
with e23AON relative to e23AON alone for dystrophin immunoflu-
orescence intensity in the quadriceps (p = 0.0032) and for dystro-
phin-positive fibers in the quadriceps (p = 0.0069) and diaphragms
(p = 0.0035) (Figures 4A–4D and S4). Statistical significance was
not achieved for dystrophin immunofluorescence intensity in the dia-
phragm when analyzed independently (p = 0.086). However, the
meta-analysis of p values from the quadriceps and diaphragm
strongly supports an effect of dantrolene in combination with
Figure 3. Dantrolene Boosts e23AON to Promote RNA Exon 23 Skipping
(A) Effect of dantrolene on e23AON induction ofDmd exon 23 skipping as determined
by the ratio of skipped/(skipped + unskipped) DMD mRNA for the quadriceps and
diaphragm. mRNA from each muscle in each treatment group was quantified
independently. Each point represents a single mouse; zDantrolene was dosed at 30–
70 mg/kg/day. (B) p values from the statistical assessment of the additional contri-
bution of dantrolene to e23AON treatment for exon 23 skipped/(skipped + unskipped)
transcript as measured by ddPCR. p values are from Friedman’s test, a two-way
nonparametric ANOVA, and a meta-analysis of the results across muscles.
Figure 2. 6-Month Treatment with 10, 50, and 300 mg/kg e23AON with
Dantrolene Did Not Adversely Affect Serum Biomarkers and
Histopathology
The levels of the following serum enzymes were analyzed: g-glutamyltransferase
(GGT) (U/L), creatinine (mg/dL), total bilirubin (mg/dL), and blood urea nitrogen
(BUN) (mg/mL). A significant reduction in BUN levels was observed with the addition
of dantrolene in mice receiving 0, 10, 50, and 300 mg/kg e23AON when compared
to their e23AON-only counterparts. (*p % 0.05 compared to e23AON-only
control; #p % 0.01 compared to e23AON-only control; yp % 0.001 compared to
e23AON-only control. Two-tailed t test) Error bars indicate one SD.
www.moleculartherapy.orge23AON relative to e23AON alone based on dystrophin immunoflu-
orescence (p = 0.0025) and dystrophin-positive fibers (p = 0.00028,
Figure 4C). The effect size is considerable in some instances. For
example, at 300 mg/kg e23AON, the dantrolene co-administration
resulted in an average doubling of dystrophin fluorescence from
13.9% to 27.5% and percentage of positive fibers from 12.6% to
23.1% of levels observed in control C57Bl6 mice in the quadriceps
(Figures 4A and 4B).
Combination therapy boosted dystrophin protein expression relative
to e23AON treatment alone, as measured by western blot analysis of
total protein in the quadriceps (Figures 5A and 5B), with a high level
of significance (p = 0.0054, Figures 5C and S5). Increases were on the
order of 1%–1.7% of the amount of dystrophin typically observed in
non mutant C57Bl6 mice quadriceps, distributed across a subset of
fibers (Figure 4D).
To determine whether the increase in dystrophin observed with
co-administration of dantrolene helps promote sarcolemmal DGC
protein stability, we assessed the effect of dantrolene on other
members of the DGC. Long-term dantrolene combined with
e23AON administration rescued the sarcolemmal localization of
botha-sarcoglycan andb-dystroglycan, indicators ofDGC rescue. Fig-
ure 6 shows images from the 50mg/kg e23AON treatment group (Fig-
ure 6); similar results were seen at 10 mg/kg and 300 mg/kg e23AON
(data not shown). Immunostaining of skeletal muscle demonstrated
positive staining at theN terminus, rod domain, andC terminus of dys-
trophin (Figure S6). Serial sections of the quadriceps and diaphragm
indicate that dystrophin-positive fibers colocalized with fibers express-ing DGC proteins. Together, these findings demonstrate that dantro-
lene boosts e23AON activity during long-term treatment to facilitate
restoration of dystrophin protein, with sufficient functionality to
enable DGC rescue and localization to the sarcolemma.
Dantrolene/e23AON Combination Therapy Reverses Pathology
to a Greater Extent than e23AON Alone
Serum creatine kinase (CK) levels are an indicator of muscle fiber
integrity because muscle CK leaks into the serum upon membrane
damage. After 6 months of treatment, serum CK levels in mdx mice
were reduced in response to e23AON, as expected. These levels
were further reduced significantly with daily oral dantrolene supple-
mentation across all e23AON treatments combined (p < 0.0001, Fig-
ures 7A, 7B and S7). In keeping with a previous report,mdx treatment
with 40 mg/kg dantrolene alone lowers CK to some extent but not to
the same degree as treatment with dantrolene and e23AON com-
bined.31 However, the high degree of rescue induced by each dantro-
lene and phosphorodiamidate morpholino oligomer (PMO) alone
precludes distinguishing between a synergistic versus additive effect.Molecular Therapy: Nucleic Acids Vol. 11 June 2018 183
Figure 4. Dantrolene Boosts e23AON to Promote Rescue of Dystrophin
Immunofluorescence Intensity and Percentage of Dystrophin-Positive
Fibers
(A) Effect of dantrolene on e23AON-induced skipped dystrophin protein as
measured by quantitative immunofluorescence of individual quadriceps and
diaphragms stained with an anti-dystrophin antibody (MANDYS8) that recognizes
the rod domain of dystrophin. One cross-section per muscle per animal was
evaluated for total dystrophin signal above a minimum background threshold and
normalized to total cross-sectional area as described in the methods. Data are
presented as a percentage of C57 control levels of dystrophin. (B) Effect of
dantrolene on e23AON-induced expression of dystrophin protein in mdx mice
treated for 6 months as measured by % dystrophin-positive fibers in individual
quadriceps and diaphragms. One cross-section per muscle per animal was
Molecular Therapy: Nucleic Acids
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topathology, we quantitated (1) ongoing regeneration of myofibers
by assessing embryonic myosin heavy chain (eMHC) expression
and (2) degeneration/regeneration by assessing myofiber centronu-
cleation.32–37 In the mdx model, muscle injury leads to increases in
regeneration/degeneration, and eMHC and centronucleation are
each anticipated to decrease with dystrophin rescue. eMHC and cen-
tronucleation were both decreased in response to e23AON treatment
alone (Figures 8A, 8D, and S8).
Dantrolene co-administration caused a decrease in centronucleation in
the diaphragm to a high degree of certainty when examined across all
e23AON treatments combined (p = 0.017, Figures 8A, 8D, and S8).
Although statistical significance was not observed when centronuclea-
tion in the quadriceps was analyzed independently, there was a trend
toward less centronucleation when analyzed together (p = 0.066).
Dantrolene, when co-administered with e23AON, is also observed to
cause a decrease in eMHC-positive fibers relative to e23AON alone in
the quadriceps (p = 0.021) and diaphragm (p = 0.025) to a high degree
of certainty based on the multivariate analysis (Figures 8B–8D and S8).
Meta-analysis of the p values from the quadriceps and diaphragm
combined supports an effect from dantrolene/e23AON treatment
relative to e23AON alone on both centronucleated fibers (p = 0.0087)
and eMHC-positive fibers (p = 0.0045, Figure 4C). These findings
demonstrate that dantrolene boost can impact mdx pathophysiology,
which is predicted to impactmuscle function, and highlights the poten-
tial of combination therapy to improve therapeutic outcome.Meta-Analyses Show that Dantrolene Significantly Boosts the
AON Effect on All Quantitative Outcomes
The levels of significance of dantrolene boost across both muscles are
shown side by side in Table 1. Taken together, our meta-analyses
demonstrate that dantrolene boosts the e23AON effect on all quanti-
tative outcomes of exon skipping, dystrophin expression, and patho-
physiology measured when considered across both muscles com-
bined, with a high level of significance (p = 0.00012–0.0087).DISCUSSION
Here, we provide preclinical mouse data in support of re-purposing
dantrolene to boost AON-guided DMD exon skipping. Dantrolene
is already FDA approved for both malignant hyperthermia and spas-
ticity38 and has been used broadly in the pediatric population. Whenevaluated for dystrophin expression. zDantrolene was dosed at 30–70 mg/kg/day.
(C) p values from the multivariate assessment of the effect of dantrolene on
e23AON treatment for dystrophin immunofluorescence quantitation and
dystrophin-positive fibers. p values from the statistical assessment of the addi-
tional contribution of dantrolene to e23AON treatment for exon 23 skipped/
(skipped + unskipped) transcript as measured by ddPCR. p values are from
Friedman’s test, a two-way nonparametric ANOVA, and a meta-analysis of the
results across muscles for dystrophin immunofluorescence quantitation. (D) Effect
of dantrolene on e23AON sarcolemmal dystrophin expression as illustrated by
representative images from the quadriceps and diaphragms of mdx mice after
treatment with e23AON ± dantrolene. Scale bar, 50 mm.
Figure 5. Dantrolene Boosts e23AON to Promote
Rescue of Dystrophin Protein after Chronic
Treatment
(A) Western blot demonstrating the effect of dantrolene on
e23AON-induced expression of total dystrophin protein in
mdx mice treated for 6 months. Protein from each muscle
of mice in all treatments group was isolated and quantified
independently. zDantrolene was dosed at 30–70 mg/kg/
day. (B) Representative western blots for dystrophin protein
expression from quadriceps are shown. C57BL/6 protein
was loaded at 25%, 12.5%, and 6.25% dilutions (diluted in
protein samples from mdx mice to serve as a standard).
(C) p values from the multivariate assessment of the effect
of dantrolene on e23AON treatment for dystrophin protein
by western blot. p values are from Friedman’s test, a two-
way nonparametric ANOVA, and a meta-analysis of the
results across muscles.
www.moleculartherapy.orgused in combination with e23AON, 30–70 mg/kg/day dantrolene
modestly increased e23-skippedmRNA, dystrophin protein expression,
and rescue of pathophysiology after 6 months of chronic dosing in the
mdx DMD mouse model. We used a dosing scheme more compatible
with human DMD treatment than our previous studies,25 which relied
on2Xdaily i.p. dantrolene injection, attempting tomore closely approx-
imate a regimen of chronic oral dosing of dantrium in humans.
Although no published study exactly recapitulates our dosing scheme,
two published studies report a higher degree of dystrophin rescue in
mdx mice than reported here after long-term treatment with similar
doses of PMO.26,27 The reason for this is unclear. Possible explana-
tions for differences observed between studies include timing of
dosing, length of study, quantitation or injection of the input mor-
pholino, or sensitivity of the methods used to measure dystrophin.
Of note, the dystrophin output reported in the two published
studies also vary by two-fold, implying that either dosing or differ-
ences in laboratory protocol can impact reported rescued dystrophinMolecularlevels.26,27 Regardless, because we observed a
significant dantrolene boost effect across a wide
range of PMO doses, such differences do not
greatly impact the conclusion reached that dan-
trolene has observed efficacy as a skip booster
at a range of PMO doses and dystrophin induc-
tion. The modest 32%–37% relative fold change
with dantrolene treatment reported in Table 1
is averaged across all e23AON concentrations
tested, including no AON, which underestimates
the true effect size at a given AON dose. There is
an apparent correlation that at higher doses of
e23AON, there was a large effect of dantrolene
co-administration.
Mouse to human equivalence formulas would
predict that a 30 mg/kg/week Exondys51 dosing
in boys weighing 20 kg would be equivalent to240 mg/kg weekly dosing in mice.39 However, the AON exon-
skipping drug appears not to scale typically from mouse to dog using
standard equivalence formulas based on surface area and therefore is
unlikely to scale typically in humans.40 In our experiments, the
300 mg/kg e23AON dose induces 7.2% dystrophin, distributed across
12.6% of the quadriceps fibers. By comparison, ExonDys51 induces
significantly less dystrophin in DMD boys, on average 0.93%
(range, 0%–2.47%), distributed across 16% of fibers (range, 1.4%–
33.5%15–21). At 50 mg/kg e23AON, we observed, on average, 5.1%
dystrophin distributed across 7.1% of quadriceps fibers, whereas
10 mg/kg yields 3.9% dystrophin across 3.4% of fibers. Although
none of these doses perfectly approximate the reported data from
humans treated with 30–50 mg/kg/week, based on measures of dys-
trophin rescue, we have demonstrated a dantrolene effect across doses
that span a broad range of AON, including concentrations most likely
to recapitulate approved dosing of 30 mg/kg/week Exondys51.
Therefore, dantrolene promotes skipping activity in the mouse model
and has high potential in humans when used in combination withTherapy: Nucleic Acids Vol. 11 June 2018 185
Figure 6. Dantrolene/e23AONCombination Therapy Restores Sarcolemmal
Dystrophin and DGC after Chronic Treatment
Effect of dantrolene/e23AON combination therapy on rescue of DGC components
as illustrated by representative immunofluorescence images of serial cross-sections
from treated mdx quadriceps. Dystrophin was detected with an antibody specific to
the rod domain (MANDYS8). Additional DGC components, a-sarcoglycan and
b-dystroglycan, were detected with NCL-a-SARC and NCL-b-DG antibodies,
respectively. zDantrolene was dosed at 30–70 mg/kg/day.
Figure 7. Creatine Kinase Reduction Is Boosted with Dantrolene/e23AON
Combination Therapy
(A) A reduction in creatine kinase levels with the addition of dantrolene in mice
receiving 0, 10, and 50mg/kg e23AON/dantrolene combination. (B) p values from the
multivariate assessment of the effect of dantrolene on e23AON treatment for serum
CK levels. p values from the statistical assessment of the additional contribution of
dantrolene to e23AON treatment for exon 23 skipped/(skipped + unskipped)
transcript as measured by ddPCR. p values are from Friedman’s test, a two-way
nonparametric ANOVA, and meta-analysis of the results across muscles.
Molecular Therapy: Nucleic Acidscurrently available Exondys51 dosing. However, it will be important
to test dantrolene/Exondys51 efficacy in the context of a human
DMD trial to establish safety and efficacy prior to wide adoption
and implementation in clinical practice.
The pivotal Exondys51 trial used to support accelerated approval
relied on 30–50 mg/kg weekly dosing in humans and is consistent
with a functional benefit in boys with DMD.17 At accelerated
approval, the FDA suggested that exploring higher and/or more
frequent Exondys51 dosing to increase the amount of dystrophin
induced and better observe clinical efficacy is necessary. However,
increasing the frequency of dosing of Exondys51 is unlikely to be
practical, and it is unclear if higher dosing is feasible from a toxicity
perspective.41 AON modifications that promise better muscle cell
uptake, such as peptide linkages, and that use skip boosting agents
represent alternative approaches to increasing dystrophin levels. In
addition to our identifying dantrolene boost activity,25 others have
reported skip boosting using CELF2a inhibitors, 6-thioguanine,
NOL8 protein, and carbohydrate-based infusions.40,42–45 However,
dantrolene is the only FDA-approved drug with previous exposure
in boys with DMD and a good safety profile.
We have previously published that dantrolene boosts AON exon 51
skipping in human patient fibroblast-derived myotube cultures.25
Our published findings showing that dantrolene can boost skipping
in combination with either AON or 2-o-methyl AON chemistries
may indicate that dantrolene boost is agnostic to AON chemistry.25
Dantrolene is an FDA-approved drug indicated for chronic use for
spasticity (1.6–6.5 mg/kg/day38) and acutely for malignant hyperther-
mia (4–8 mg/kg38) and has been widely studied in multiple animal186 Molecular Therapy: Nucleic Acids Vol. 11 June 2018models and humans.46–50 It targets the RyR1, which is responsible
for Ca2+ release from the sarcoplasmic reticulum (SR) and regulating
levels of cytosolic and SR luminal Ca2+ levels essential for excitation-
contraction coupling.
In the current study, we measured dantrolene serum levels to be an
average of 0.26 mg/mL ± 0.18, which is at the low end of the known
therapeutic range used in humans (0.37 to 1.24 mg/mL).46,51,52
Together with findings that other RyR calciummodulators, like RyCal
S107, can also boost exon skipping, it is likely dantrolene boost activ-
ity results from RyR calcium modulation.53–55 Calcium regulation of
alternative splicing has been described in other models.56–58
In DMD, RyR has been shown to be dysregulated and contributes to
increased intracellular calcium and DMD pathology.5 As a potential
means of controlling calcium-handling defects in DMD, Bertorini
et al.59 administered 8 mg/kg/day dantrolene to 7 DMD boys over a
2-year period. In those studies, dantrolene was well tolerated in 6/7
patients; one boy experienced increased, but mild, muscle weakness
that was reversed upon lowering the dose to 6 mg/kg/day. A trend to-
ward reducingmanual muscle testing deterioration was observed, and
a statistically significant reduction in CK levels was reported.
Although the data were insufficient to establish a clear functional
benefit, this study demonstrates long-term treatment with dantrolene
can be tolerated in children with DMD.
We demonstrated reduced CK levels in mdx mice treated with
dantrolene alone, but observed no effect on any other measures of
mdx histopathology or exon skipping in the absence of e23AON,
Figure 8. Dantrolene/AONCombination Therapy Reduces Centronucleation
in the Diaphragm and eMHC-Positive Fibers in the Quadriceps
(A) Cross-sections of diaphragm muscles were stained with H&E, highlighting
centronucleated fibers, and the percentage of fibers with centrally located nuclei was
counted. Cross-sections of diaphragm (B) and quadriceps (C) muscles were
stained with anti-eMHC, highlighting regenerating fibers. zDantrolene was dosed at
30–70 mg/kg/day. (D) p values from the multivariate assessment of the effect of
dantrolene on e23AON treatment for centronucleation and eMHC-positive fibers. p
values from the statistical assessment of the additional contribution of dantrolene to
e23AON treatment for exon 23 skipped/(skipped+ unskipped) transcript asmeasured
by ddPCR. p values are from Friedman’s test, a two-way nonparametric ANOVA, and
meta-analysis of the results across muscles. Error bars indicate one SD.
www.moleculartherapy.orgconsistent with published data.31,60 In one published study in mdx
mice, 6-week 40 mg/kg dantrolene treatment reduced both CK levels
and some, but not all, measures of strength, despite no observed effect
on histopathology.31 It is reasonable to anticipate that if there is a
beneficial effect in humans, chronic administration will be necessary.
Because we observed skip boosting activity at doses in the low range
used chronically for spasticity and higher dosing has been reported to
induce mild muscle weakness in some instances,61 it would be pru-
dent to perform a dose-ranging trial in humans prior to routine use
of combination therapy for DMD.
In our studies, dantrolene boosts dystrophin levels by as much as
1%–1.7% of normal levels and allows expression in an additional
4%–10% of the fibers at the most relevant AON doses. Our findings
provide pre-clinical support and guidance for combination AON/
dantrolene therapy for enhancement of Exondys51 or other skipping
drugs in the research pipeline for DMD and perhaps other diseases to
be targeted by exon skipping. Because Exondys51 and dantrolene are
already FDA approved, our findings can be assessed rapidly in human
trials, highlighting the value of screening FDA-approved drugs for
combination therapies that promise greater efficacy.
MATERIALS AND METHODS
Long-Term Treatment Blinding
The present randomized, blinded, placebo-controlled study was per-
formed on 180 mdx mice. Factorial randomization was used and
mice were stratified into treatment groups based on animal age
and weight and randomly assigned to each treatment group. 24 or
18 mdx mice aged 4–6 weeks were used in each group. Procedures
involving all mdx mice were approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of California,
Los Angeles (UCLA). Individuals dosing the mice and performing
data-generating assays were blinded for all assays. Once all the
data were collected, the blind was lifted for the individual performing
statistics.
Mice and Tissue Preparation
Procedures involving all mdx mice were approved by the IACUC of
UCLA. For 3-week and 6-month experiments with systemic injec-
tions of e23AON, the quadriceps were harvested and the right muscle
was frozen in optimal cutting temperature compound (OCT) for
sectioning and analysis by immunohistochemistry (IHC), whereas
the left muscle was cut in half and snap frozen for analysis by western
blot and ddPCR. For the diaphragm, one-half of the muscle was
designated for IHC and one-fourth was designated for western blot
and RT-PCR. Mice and chow were weighed weekly.
AON and Dantrolene Administration to mdxMice
e23AON morpholino62 (50-GGCCAAACCTCGGCTTACCTGAA
AT-30; provided by Sarepta Therapeutics) was injected intravenously
(retro-orbitally) in 100 mL saline. For 3-week experiments, Revonto
(dantrolene sodium NDC 27505-001-65; DSM Pharmaceuticals) was
resuspended inwater and administered byoral gavage in a 100-mL bolus
twice daily. For 6-month experiments, control and experimental feedMolecular Therapy: Nucleic Acids Vol. 11 June 2018 187
Table 1. Friedman’s Test, Two-Way Nonparametric ANOVA, of the Addition of Dantrolene to e23AON Treatment for Study Outcomes and Meta-Analyses of
the p Values across Muscle Types
Outcome Measure n
Relative Fold Change with Dantrolene
Treatment
Quadriceps
(p Value)
Diaphragm
(p Value)
Serum
(p Value)
Meta-Analysis
(p Value)
Exon 23 skipped/(skipped + unskipped) transcript
(%)
124 1.37 0.012 0.0008 – 0.00012
Dystrophin immunofluorescence quantitation (%
C57)
152 1.33 0.0032 0.086 – 0.0025
Dystrophin-positive fibers (%) 154 1.42 0.0069 0.0035 – 0.00028
Dystrophin protein by western blot (%C57) 131 1.23 0.0054 – – –
Centronucleated fibers (%) 47 0.97 0.066 0.017 – 0.0087
eMHC-positive fibers (%) 47 0.83 0.021 0.025 – 0.0045
Serum CK 132 0.49 – – <0.0001 –
Shown is a summary of statistical analysis described in Figures 3B, 4C, 5C, 7B, and 8D.
Molecular Therapy: Nucleic Acidswas formulated into 58YP chow at 0, 1,121, and 1,328 ppm. Dantrium
from capsules (NDC 0115-4433-1 GlobalRPH) (Lot 10007332) was
incorporated into chow and irradiated (Newco Distributors) and
mice were given ad libitum access to chow. To ensure continued expo-
sure to target levels of dantrolene, mice were weighed at week 13 and
chow dantrolene concentration was adjusted to 1,328 ppm, where
appropriate. The amount of chow consumed was weighed weekly and
dantrolene dose was adjusted by bodyweight.
RNA Isolation, qPCR, and ddPCR
Total RNA was isolated from frozen skeletal muscle with the
QIAGEN RNeasy Fibrous Tissue Kit and reverse transcribed to
cDNA using the iScript cDNA Synthesis Kit (Bio-Rad). The final
concentration of digested total DNA was adjusted to fall within
the linear range for the Poisson calculation for the expected
number of droplets in the digital PCR. Each sample was partitioned
into 15,000 droplets on a DG8 cartridge (Bio-Rad) and each droplet
was amplified by PCR using the following protocol: initial denatur-
ation step at 95C for 10 min, 40 cycles of 94C for 30 s, and 60C
for 60 s, followed by 98C for 10 min. Primer-probe sets to assess
specific full-length or skipped Dmd exon 23 mRNAs have been
previously described.25 For amplification of exons from 22 to 24;
the percentage of exon skipping was expressed as the total exon
23 skipped transcript as a percentage of total (skipped + unskip-
ped) Dmd transcript. Samples were loaded onto the QX200 droplet
reader, and ddPCR data were analyzed with QuantaSoft analysis
software.63 The target concentration in each sample was expressed
as copies per ng.
Measurement of Serum Creatine Kinase, g-Glutamyl
Transpeptidase, Creatinine, Total Bilirubin, and Blood Urea
Nitrogen
Blood was collected by retro-orbital bleeding of the mice. After clot-
ting, samples were spun at 6,000 rpm at 4C. Serum was collected,
snap frozen in liquid nitrogen, and stored at 80C. Creatine kinase
analysis was performed with the Genzyme Creatine Kinase kit
(BioPacific Diagnostic). g-glutamyl transpeptidase, creatinine, total188 Molecular Therapy: Nucleic Acids Vol. 11 June 2018bilirubin, and blood urea nitrogen measurements were performed
by the UCLA Division of Laboratory Animal Medicine (DLAM)
Pathology and Laboratory Medicine Services.
Measurement of Dantrolene Serum Levels
Blood was collected by retro-orbital bleeding of the mice. After clot-
ting, samples were spun at 6,000 rpm at 4C. Serum was collected,
snap frozen in liquid nitrogen, and stored at 80C. Dantrolene
serum analysis was performed with the Dantrolene ELISA Kit
(Neogen; Product #106319; Lot 140923). Samples were run in dupli-
cate. A standard curve was run on each plate to ensure sensitivity of
the assay (Figure S2B). Diluted dantrolene solution was used to
generate a standard curve.
Western Blot Protocol
Total protein was isolated from flash-frozen quadriceps and dia-
phragms from the treated MDX and control C57 mice. Tissues
were homogenized in Mito buffer (0.2 mM EDTA, 0.25 mM sucrose,
and 10 mM tris-HCl [pH 7.4]) with protease/phosphatase inhibitor
cocktail (Pierce) and deoxyribonuclease/ribonuclease and subjected
to low-speed (3,000 g) centrifugation for 10 min at 4C. The super-
natant was centrifuged at 100,000 g (high-speed centrifugation) for
1 hr for isolation of membrane fraction. Isolated membranes and
pellet after low-speed centrifugation were combined and resuspended
in 300 mL extraction buffer (50 mM tris-HCl [pH 7.4], 7 M urea, 2 M
thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propane-
sulfonate (CHAPS), 2% SDS, and 50 mM b-mercaptoethanol). Pro-
tein concentration was determined by 2-D Quant Kit (GE Healthcare
Life Sciences).
40 mg total protein were run on a 6% polyacrylamide gel and trans-
ferred onto a nitrocellulose membrane for 2 hr at 4C. The membrane
was blocked for 1 hr in 5% milk and then incubated with MANDYS8
(Sigma) (anti-dystrophin), 1:400 in Tris-buffered saline with tween
(TBS-T), hVin-1 (Sigma), 1:5,000 in TBST (antivinculin), and a skel-
etal muscle membrane protein not associated with the DGC that was
used as a loading control.
www.moleculartherapy.orgFor analysis, dystrophin protein levels were normalized to the loading
and then pooled across treatment groups to determine the average
dystrophin rescue. Serial dilutions of C57 sample into untreated
MDX sample were run simultaneously. All western data included
were run through quality control, as defined by linearity of dilution
of C57 controls. The average densitometry value for 100% of dystro-
phin in C57 was calculated as the mean of the densitometry values of
C57 serial dilutions multiplied by the dilution factor. Densitometry
analysis was performed with the ImageLab 5.1 gel documentation
system (Bio-Rad).
Histology and Immunofluorescence
IHC was performed on unfixed 10-mm tissue sections using the
MouseOnMouse kit (Vector Labs). IHC assessment used the
following primary antibodies: MANDYS8 (dystrophin rod
domain), Ab15277 (dystrophin C terminus; Abcam), and Manex1A
(dystrophin N terminus; Developmental Studies Hybridoma Bank).
a-Sarcoglycan was detected with NCL-a-SARC (Novocastra), and
b-dystroglycan was detected with NCL-b-DG (Novocastra), eMHC
(DSHB; BF-G6-c), and DNA with DAPI. Secondary labeling was per-
formed with fluorescein isothiocyanate (FITC) anti-mouse or FITC
anti-rabbit (Vector Labs). Sections were mounted in Vectashield
Mounting Medium (Vector Labs). Fluorescent images were acquired
and analyzed using Ariol SL-50 (Applied Imaging, San Jose, CA). The
Ariol scanner is based on an Olympus BX61 microscope with motor-
ized stage and autofocus capabilities, equipped with a black and white
video camera (Jai CVM2CL). Scanning and analyses were performed
through the Translational Pathology Core Laboratory, Department of
Pathology and Laboratory Medicine, David Geffen School of Medi-
cine at UCLA. For quantifying dystrophin immunofluorescence, the
minimum threshold was placed above background level for all sec-
tions. Analytical readouts included area of immunofluorescence
(IFL) signal (area of signal above the signal threshold) and total
area of the section. The total area of positive pixels above the mini-
mum threshold per muscle section was counted using AxioVision
Rel.4.6.3.0 acquisition software. Each sample’s dystrophin immuno-
fluorescent levels are expressed as a percentage of area of positive
pixels in C57 (100%). For quantifying dystrophin-positive fibers,
the minimum threshold was placed above background level for all
sections. For each sample, fibers were counted across the entire sec-
tion. Dystrophin-positive fibers were defined as fibers that had sarco-
lemmal dystrophin expression above background and surrounding
>75%–80% of each fiber. For both measurements, all of our readings
were well below the maximal intensity threshold (pixel saturation was
avoided). For detecting DGC-associated proteins by IHC, 2 mice
from each treatment group, including non-treated mdx controls,
were selected and the samples were blinded. Samples were stained
and entire cross-sections were visualized. While blinded, representa-
tive fields for each sample were taken. A subset of these images is
included as Figure 6. For quantifying centronucleation, eMHC-
positive fibers, diaphragms, and quadriceps from the 3 to 6 mice
per treatment group, which had total dystrophin levels by western
blot near the median, were selected. The average percentage of fibers
with centrally located nuclei in the diaphragm per group was deter-mined by counting entire muscle cross-sections. For quantifying
eMHC-positive fibers, quadriceps/diaphragms from 6 mice per
group, which had total dystrophin levels by western blot near the
median, were selected. The total number of eMHC-positive fibers
were counted and compared to the total number of muscle fibers
per section. For pathology, a standard protocol was used for H&E
staining. All mouse livers, hearts, and kidneys were reviewed blindly
by a certified pathologist.
Statistical Analysis
We selected to test whether dantrolene makes an additional contribu-
tion to the outcomes beyond E23AON using a 2-way ANOVA with
interactions. However, we observed that the outcomes data are not
normally distributed, and performed a nonparametric version of
analysis using Friedman’s test using SAS software (version 9.4, SAS
Institute, Cary, NC). We ran each analysis on the ranks of the obser-
vations for each of the 7 traits (or assays). Quadriceps, diaphragm, and
serum were analyzed separately. Each test included E23AON first,
followed by dantrolene and the possibility of their interaction. None
of the interactions were significant. The separate outcome results
were combined bymeta-analyses across muscle types, resulting in tests
of 6 non-independent traits. A 0.01 level of significance was set to ac-
count for multiple testing of 6 traits that are not independent. For each
outcome, E23AON was highly significantly (p < 0.0001), except for
centronucleated fibers in the quadriceps (p < 0.04) (data not shown).
Table 1 presents the p values for dantrolene for each of the outcomes.
A standard protocol was used for H&E staining. The average percent-
age of fibers with centrally located nuclei in the diaphragm per group
was determined by counting 750–1,000 fibers from the 3 mice per
group, which had total dystrophin levels by western blot nearest the
median. All mouse livers, hearts, and kidneys were reviewed blindly.
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